Clear Eyes eye drops recalled over sterility concerns
Prestige Consumer Healthcare's Medtech Products Inc. is voluntarily recalling nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to sterility concerns, although no active contamination has been identified. The FDA classified this as a Class II recall, meaning serious health consequences are unlikely. Consumers are advised to stop using the product and may seek refunds from retailers.
Is Prestige Consumer Healthcare’s (PBH) Upgraded 2027 Outlook and Halted Buybacks Reframing Its Growth Story?
Prestige Consumer Healthcare (PBH) has raised its fiscal 2027 outlook, projecting revenues of US$1.29-US$1.32 billion and GAAP diluted EPS of US$4.18-US$4.28, driven by new acquisitions. This updated guidance, alongside a halt in buybacks and an upcoming SVP of Operations retirement, aims to reframe the company's growth narrative, emphasizing the impact of recent acquisitions and supply chain investments despite underlying risks. The article also highlights a fair value estimate of $66.80 for PBH, suggesting a 32% upside.
Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH
Rice Hall James & Associates LLC has acquired 689,692 shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) worth approximately $32.6 million, making it one of their largest holdings with a 1.46% stake. Institutional ownership of PBH remains high at 99.95%, with several other investment firms also increasing their positions. Despite exceeding quarterly earnings and revenue expectations, PBH shares traded down 2.8%, and analysts currently maintain a "Hold" rating with an average price target of $70.75.
Prestige Consumer Healthcare Announces Operations Leadership Transition
Prestige Consumer Healthcare (PBH) announced that Senior Vice President of Operations, Jeffrey Zerillo, will retire on August 14, 2026, marking a leadership transition. Analysts have issued a Buy rating with a $72.00 price target for PBH, while TipRanks' AI Analyst, Spark, rates it as Outperform due to strong financial performance and a supportive earnings outlook. The company specializes in over-the-counter health and wellness products in North America.
ETFs Investing in Prestige Consumer Healthcare Inc Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold stocks of Prestige Consumer Healthcare Inc. The list, sorted by market value, includes various ETFs with details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs predominantly focus on small-cap and healthcare sectors, offering diversified investment opportunities.
Prestige Consumer Healthcare's Jeffrey Zerillo to Retire as SVP, Operations
Prestige Consumer Healthcare announced that Jeffrey Zerillo, their Senior Vice President of Operations, will be retiring effective August 14, 2026. This information is based on an SEC filing (8-K) by Prestige Consumer Healthcare Inc. (PBH).
Prestige Consumer Healthcare Inc. Announces Retirement of Jeffrey Zerillo from Senior Vice President, Operations, Effective August 14, 2026
Prestige Consumer Healthcare Inc. announced the retirement of Jeffrey Zerillo from his position as Senior Vice President, Operations, effective August 14, 2026. Mr. Zerillo also notified the company of his decision to retire from all other positions he holds within the company on the same date. The announcement was published on August 14, 2026.
Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating
Zacks Research has upgraded Prestige Consumer Healthcare (NYSE:PBH) from a "strong sell" to a "hold" rating. This upgrade comes after the company exceeded quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% increase year-over-year. The consensus analyst rating for PBH is now "Hold" with an average price target of $70.75.
Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 10:00 a.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. The company markets and distributes a diverse portfolio of consumer healthcare products globally.
Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH
Quantinno Capital Management LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by acquiring 19,281 shares, bringing its total holdings to 36,990 shares valued at $2.19 million. Institutional investors collectively own 99.95% of PBH. The company also surpassed quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% year-over-year increase.
Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH
Renaissance Technologies LLC significantly reduced its stake in Prestige Consumer Healthcare Inc. (PBH) by 62% in the first quarter, selling 59,900 shares but retaining 36,702 shares valued at approximately $2.17 million. Despite this, institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare reported strong quarterly results, exceeding EPS estimates and showing a 6.5% year-over-year revenue increase, with the company issuing fiscal 2027 EPS guidance of $4.55–$4.65.
Prestige Consumer Healthcare (PBH) Is Up 5.6% After Raising Fiscal 2027 Outlook on Acquisitions
Prestige Consumer Healthcare (PBH) saw its stock rise by 5.6% after reporting its fiscal 2027 first-quarter results and subsequently raising its full-year outlook. The company's updated revenue guidance of US$1.29 billion–US$1.32 billion and GAAP diluted EPS guidance of US$4.18–US$4.28 are primarily driven by recent acquisitions, including Breathe Right and LaCorium Health, despite ongoing supply constraints for Clear Eyes. This shift places a greater focus on the successful integration of acquired brands to offset margin pressures and operational challenges.
Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
Prestige Consumer Healthcare Inc. announced that CFO and COO Christine Sacco and VP of Investor Relations, Treasury, & Business Development Phil Terpolilli will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. A live webcast and replay of the event will be available on the company's website. The company markets and distributes various consumer healthcare products globally.
Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August 12, 2026, at 10:00 a.m. ET and will be webcast live on the company's investor relations website. A replay will also be available for those unable to attend the live session.
Prestige Consumer Executives Set for Aug. 12 Fireside Chat
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 10:00 a.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. This event follows a previous conference notice that saw a 3.83% positive reaction, with analysts noting the historical context and a current 6.61% short interest as factors to monitor.
Prestige Consumer Healthcare (PBH) Following Its 2027 Outlook Raise And The Undervalued View
Prestige Consumer Healthcare (PBH) has raised its fiscal 2027 revenue and earnings outlook, projecting revenue between $1.29b and $1.32b and GAAP diluted EPS between $4.18 and $4.28, driven by the integration of two recent acquisitions. Despite a mixed share price performance over the past year, the company's valuation narrative suggests it is 18.5% undervalued with a fair value of $66.80 per share. However, risks such as supply chain recovery challenges and increased e-commerce competition remain.
Prestige Consumer Healthcare Q1 Earnings Call Highlights
Prestige Consumer Healthcare reported a 6.5% revenue growth in Q1 fiscal 2027, reaching $265.7 million, exceeding sales and earnings expectations. This growth was driven by strong category performance, the Breathe Right acquisition, and retailer order timing. The company also raised its full-year outlook to include recent acquisitions while maintaining its organic revenue growth forecast.
Prestige Consumer Healthcare Inc. $PBH Shares Bought by First Trust Advisors LP
First Trust Advisors LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by 137.5% in the first quarter, now owning 37,395 shares valued at approximately $2.2 million. The company exceeded quarterly expectations with adjusted EPS of $0.98 and revenue of $265.7 million, leading to raised fiscal 2027 guidance. However, analyst sentiment is mixed, with an average "Hold" rating and concerns regarding declining GAAP earnings, margins, and substantial net debt from recent acquisitions.
Prestige Consumer Healthcare Inc (PBH) (Q1 2027) Earnings Call Highlights: Record Cash Flow and ...
Prestige Consumer Healthcare Inc. (PBH) reported exceeding sales and earnings expectations in Q1 fiscal 2027, with total sales up 6.5% to $266 million and record adjusted free cash flow of $83.7 million. The company successfully integrated the Breathe Right acquisition and completed another strategic acquisition (Lacorium Health), collectively expected to add over 20% to annualized revenue. Despite some challenges like ClearEyes supply constraints and higher transportation costs, management raised full-year fiscal 2027 adjusted diluted EPS guidance to $4.55-$4.65 and adjusted free cash flow to $270 million or more.
Prestige Consumer Healthcare Inc (PBH) (Q1 2027) Earnings Call Highlights: Record Cash Flow and ...
Prestige Consumer Healthcare Inc (PBH) reported strong Q1 fiscal 2027 results, exceeding sales and earnings expectations with a 6.5% increase in total sales and record adjusted free cash flow. The company successfully integrated acquisitions, raised full-year guidance, and continues to see robust consumption in key categories. Despite some challenges like ClearEyes supply constraints and higher transportation costs, management remains optimistic about future growth and strategic initiatives.
Breathe Right and LaCorium Acquisitions Raise Prestige Consumer's 2027 Outlook
Prestige Consumer Healthcare reported strong Q1 fiscal 2027 results with revenue up 6.5% to $265.7 million and adjusted diluted EPS rising to $0.98. The company's recent acquisitions of Breathe Right and LaCorium Health significantly contributed to these results and led to a raised fiscal 2027 outlook for revenue, adjusted diluted EPS, and adjusted free cash flow. Despite an increase in net debt to approximately $2.0 billion due to financing for acquisitions, the company is well-positioned for future growth.
Prestige Consumer Healthcare Inc. 2026: Revenue $265.71M, EPS $0.61— 10-Q Summary
Prestige Consumer Healthcare Inc. reported a Q2 2026 revenue increase to $265.71M, up 6.5% year-over-year, driven by growth in both North America and International markets. Despite revenue growth, net income and diluted EPS declined by 38.5% and 35.8% respectively compared to the prior-year quarter. The company expanded its Wellness category through acquisitions but faced challenges with sterile eye-care supply constraints and operational investments impacting margins.
Press Release: Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare Inc. reported its fiscal 2027 first-quarter results. The company's press release provides financial performance details for the quarter. This announcement is significant for investors and stakeholders tracking the company's financial health and operational progress.
Press Release: Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
This document is a press release from Prestige Consumer Healthcare Inc. reporting its fiscal 2027 first quarter results. It is the full text of the official press release as issued by the company.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare Inc. reported strong Q1 fiscal 2027 results, exceeding sales and earnings expectations with a 6.5% revenue increase to $265.7 million and adjusted diluted EPS of $0.98. The company also completed the acquisitions of Breathe Right® and LaCorium Health, leading to an upward revision of its fiscal 2027 outlook for both revenue ($1,290 to $1,315 million) and adjusted diluted EPS ($4.55 to $4.65). These acquisitions are expected to significantly contribute to future revenue and profitability.
Earnings call transcript: Prestige Consumer beats Q1 2026 estimates as stock edges higher
Prestige Consumer Healthcare reported stronger-than-expected Q1 fiscal 2027 results, with adjusted EPS of $0.98 and revenue of $265.7 million, both exceeding analyst estimates. The company saw organic revenue growth of 3.2% and a record adjusted free cash flow of $83.7 million, while integrating the Breathe Right acquisition and progressing with LaCorium. Despite a modest stock gain, the company addressed ongoing challenges such as Clear Eyes supply constraints and margin pressures, while maintaining its full-year organic growth outlook.
Prestige Consumer Healthcare (NYSE: PBH) expands with $1,045.0M wellness deal
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported its Q1 2027 earnings, revealing a 6.5% increase in total revenues to $265.7 million for the quarter ended June 30, 2026, primarily driven by the $1,045.0 million acquisition of the OTC Wellness Business, including the Breathe Right brand. Despite revenue growth, net income decreased to $29.177 million from $47.466 million year-over-year, and gross profit fell by 3.0% due to acquisition-related costs and amortization. The company also detailed subsequent events, including the $150.0 million acquisition of LaCorium Health and the issuance of $400.0 million in new senior notes to redeem existing debt.
Prestige Consumer Healthcare Inc. 2027 Q1 - Results - Earnings Call Presentation (NYSE:PBH)
Prestige Consumer Healthcare Inc. (NYSE: PBH) has released its Q1 2027 earnings call presentation. The company reported an EPS of $0.98, beating estimates by $0.10, and revenue of $265.71 million, surpassing expectations by $15.39 million with a 6.48% year-over-year increase. This presentation provides details on the financial results for the quarter.
Prestige Consumer Healthcare Inc. 2027 Q1 - Results - Earnings Call Presentation (NYSE:PBH) 2026-08-06
Prestige Consumer Healthcare Inc. (PBH) has released its Q1 2027 earnings call presentation. The company reported an EPS of $0.98, beating estimates by $0.10, and revenue of $265.71M, surpassing expectations by $15.39M, representing a 6.48% year-over-year increase. This article provides access to the slide deck published in conjunction with their earnings call.
Prestige Consumer Healthcare (NYSE: PBH) awards director 2,981 RSUs
Prestige Consumer Healthcare (NYSE: PBH) director Dawn M. Zier was granted 2,981 restricted stock units (RSUs) as part of the company's director compensation program. The RSUs, valued at $155,000 based on a $52.00 closing stock price, will vest on the first anniversary of the grant date and will be settled in common stock upon specific trigger events such as death, separation, or a change in control. Following this transaction, Ms. Zier directly holds 19,514 shares of Prestige Consumer Healthcare common stock.
Earnings Flash (PBH) Prestige Consumer Healthcare Inc. Reports Q1 Revenue $265.7M, vs. FactSet Est of $250.3M
Prestige Consumer Healthcare Inc. (PBH) reported its Q1 revenue of $265.7 million, surpassing FactSet's estimate of $250.3 million. This positive earnings flash was published on August 6, 2026, and also follows an earlier report of the company raising its earnings guidance for fiscal year 2027. The company's stock, PBH, rose after these fiscal Q1 results and lifted outlook.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding sales and earnings expectations with a revenue of $265.7 million, up 6.5%, and organic sales growth of 3.2%. The company closed the Breathe Right® and LaCorium acquisitions, which contributed to its performance and led to an upward revision of its fiscal 2027 outlook for revenue and Adjusted Diluted EPS to $1,290-$1,315 million and $4.55-$4.65, respectively. These acquisitions are expected to significantly expand the company's revenue base and become increasingly accretive to profitability and cash flow.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding sales and earnings expectations with revenue up 6.5% to $265.7 million and adjusted diluted EPS of $0.98. The company completed acquisitions of Breathe Right® and LaCorium Health, leading to a raised fiscal 2027 outlook with anticipated revenue of $1,290 to $1,315 million and adjusted diluted EPS of $4.55 to $4.65. This performance was driven by organic growth in several categories and robust adjusted free cash flow of $83.7 million.
Avoiding Lag: Real-Time Signals in (PBH) Movement
This article provides a real-time analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH) stock movements, highlighting strong near- and mid-term positive sentiment but a weak long-term outlook. It identifies key resistance levels and offers institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis and AI-generated signals for informed decision-making.
Price to sales forward of Prestige Consumer Healthcare Inc. – NYSE:PBH
This article provides financial data for Prestige Consumer Healthcare Inc. (NYSE: PBH), specifically its price-to-sales forward metric. The content appears to be a financial snapshot from a trading platform, indicating market status and general financial information for the company.
Prestige Consumer Number of Employees 2026 | Employee Count & Headcount Data
Prestige Consumer Healthcare, Inc. (PBH) had 897 employees worldwide as of March 2026, representing a 10.6% growth since 2023. The company is actively hiring, although job postings declined by 2.7% in 2026 compared to 2025. Its workforce is primarily concentrated in the United States, with significant growth in Australia, and the largest functional groups are Finance and Operations, Engineering, and Sales and Marketing.
PBH|Prestige Consumer Healthcare Inc|Price:52.180|Chg%:+0.460
Prestige Consumer Healthcare Inc. (PBH) shows healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Pharmaceuticals industry. Institutional ownership is notably high, and analysts have consistently rated the stock as "Buy," with a target price of $66.00. Despite strong market performance and fundamentals, technical indicators suggest a sideways trading pattern in the medium term.
Prestige Consumer Healthcare Inc (PBH) Institutional Confidence
Prestige Consumer Healthcare Inc (PBH) has a strong institutional confidence score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 121.63%, with John Rogers being the largest institutional shareholder. Several major institutional investors hold significant shares, with some increasing and others slightly decreasing their holdings.
PBH|Prestige Consumer Healthcare Inc|Price:50.370|Chg%:+0.710
This article provides a comprehensive stock analysis of Prestige Consumer Healthcare Inc (PBH) by TradingKey, noting its healthy fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. It highlights that institutional ownership is very high, analysts rate it as a "Buy" with a target price of $66.00, and the stock is currently trading sideways. The piece also details various aspects of Prestige Consumer Healthcare Inc's business, including its diverse product portfolio and key financial indicators.
Prestige Consumer Healthcare Inc (PBH) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides general information on Prestige Consumer Healthcare Inc (PBH) regarding its dividends and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and contains a section for the dividend timeline, which currently shows no data. The page also includes current stock performance metrics for PBH.
PBH Income Statement
This article provides a detailed quarterly and annual income statement for Prestige Consumer Healthcare Inc (PBH), enabling users to analyze the company's financial performance and operational efficiency. It covers key metrics like revenue, operating profit, and net income, alongside year-over-year comparisons. The page also includes FAQs on how to interpret these financial statements and the significance of various metrics for investors.
Prestige Consumer Healthcare Inc Revenue Breakdown – FWB:PBV
Prestige Consumer Healthcare Inc. (FWB:PBV) generated 942.30 million EUR in revenue last year. The majority of this revenue, 790.72 million EUR, came from its North American Over-the-counter Healthcare segment. The United States was the primary contributor to revenue, accounting for 736.05 million EUR.
Prestige Consumer Healthcare Inc
This article provides a brief overview of Prestige Consumer Healthcare Inc (PBH), including its stock performance, market capitalization, and P/E ratio. It also details the company's revenue breakdown by region for a past fiscal year, showing a significant portion comes from the United States, but notes that more recent financial data has not yet been disclosed.
Discipline and Rules-Based Execution in PBH Response
This article analyzes Prestige Consumer Healthcare Inc. (NYSE: PBH) using AI models, identifying a potential shift in positive near-term sentiment and broader weak alignment. It highlights an exceptional risk-reward short setup and provides institutional trading strategies for different risk profiles, including position, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal analysis, support, and resistance levels for PBH.
Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring A 33.81% Potential Upside
Prestige Consumer Healthcare (PBH) is a significant player in the healthcare sector, offering over-the-counter health and personal care products. Despite a recent revenue growth decline, the company shows potential for recovery with a promising 33.81% upside based on analyst targets, an attractive forward P/E ratio of 9.85, and strong free cash flow. Technical indicators also suggest a potential buying opportunity for long-term investors due to the stock being oversold.
how InvestingPro’s fair value spotted Prestige Healthcare’s 42% drop By Investing.com
InvestingPro's Fair Value analysis accurately predicted a 42% drop in Prestige Consumer Healthcare Inc. (NYSE:PBH) shares, flagging the stock as severely overvalued in February 2025. The stock, initially trading at $86.12, plummeted to $49.92, validating the analysis that estimated its intrinsic worth at $50.69. This case study highlights the utility of comprehensive valuation methodologies in identifying mispriced stocks and making informed investment decisions.
how InvestingPro’s fair value spotted Prestige Healthcare’s 42% drop
InvestingPro's Fair Value analysis accurately predicted a 42% drop in Prestige Consumer Healthcare Inc. (PBH) stock. In February 2025, when PBH was trading at $86.12, InvestingPro flagged it as 41% overvalued with an intrinsic worth of $50.69. This prediction was validated sixteen months later as the stock plunged to $49.92, demonstrating the tool's effectiveness in identifying mispriced stocks.
Prestige Consumer Healthcare (NYSE: PBH) issues $400M 2034 notes
Prestige Consumer Healthcare Inc., through its subsidiary Prestige Brands, Inc., announced the issuance of $400 million of 6.250% senior unsecured notes due July 15, 2034. These notes, guaranteed by the company and its domestic restricted subsidiaries, will pay interest semiannually starting January 15, 2027. The indenture includes provisions for early redemption, repurchase upon a change of control at 101% of principal, and customary covenants limiting additional indebtedness and restricted payments.
PBH4913522 Bond Profile — Key Metrics
This article provides a detailed profile of the PBH4913522 corporate bond issued by Prestige Consumer Healthcare, Inc. Key metrics include a 5.125% coupon rate, a maturity date of January 15, 2028, and an outstanding amount of $400 million. The company, founded in 1996, specializes in marketing pharmaceutical drugs and consumer products across North American and International OTC Healthcare segments.
Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a 36.61% Potential Upside in a Competitive Market
Prestige Consumer Healthcare (NYSE: PBH) is a healthcare company with a diverse portfolio of over-the-counter products, presenting a potential upside of 36.61% based on an average analyst target price of $66.80. Despite a revenue contraction, the company demonstrates resilience with strong EPS and free cash flow, focusing on reinvestment over dividends. Technical indicators suggest the stock might be entering oversold territory, signaling a potential buying opportunity.
